copper chelation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
| Property | Value | Notes |
|---|---|---|
| Copper binding sites | Imidazole, amino, and amide nitrogens | Form chelate rings with Cu(II) |
| Conditional binding constant | Reported near 10^16 at neutral pH | Value depends on method and medium |
| Visible absorption | Broad band in the blue-violet region | Source of the characteristic color |
| Common analytical methods | LC-MS, HPLC, UV-Vis, ICP-OES | Used for identity and copper content |
| Main degradation routes | Oxidation, photolysis, hydrolysis | Accelerated by light, heat, and pH extremes |
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Tandospirone, sold under the brand name Sediel, is an anxiolytic and antidepressant medication used in Japan and China, where it is marketed by Dainippon Sumitomo Pharma. It is a member of the azapirone class of drugs and is closely related to other azapirones like buspirone and gepirone. Tandospirone was introduced for medical use in Japan in 1996 and in China in 2004.
The area returned to the English crown in 1157, when Henry II of England took possession of the area (from Malcolm IV of Scotland). Henry II formed two new counties from the former earldom: Westmorland and Carliol – originally an abbreviation of the Latin Carlioliensis '[bishop] of Carlisle'. Westmorland also included areas formerly part of the Earldom of Lancaster. The lead- and silver-mining area of Alston, previously associated with the Liberty of Tynedale was later also added to the new county of Carliol for financial reasons. By 1177, Carliol had become known as Cumberland. The border between England and Scotland was made permanent by the Treaty of York in 1237. The population of Cumberland in the 1841 census was 178,038.
The article cites the attempts to replicate Hamer's work, some supportive and some not. It concludes, "Although it is encouraging that the largest study replicated some findings from smaller studies, the case is not closed. Still larger studies are needed to provide the degree of certainty now expected in molecular genetics, and in any case, the mapping case is not closed in molecular genetics until one has identified the genes that affect a trait." Hamer and colleagues also investigated the genetic roots of anxiety and found that a promoter region polymorphism in the gene for the serotonin transporter, which is the target of antidepressant drugs such as Prozac, is associated with mood and personality. This finding has been extensively replicated and extended and its activity has been confirmed by direct brain imaging studies. In 2004, Hamer used data from ongoing behavioral genetics studies in his lab to explore the possibility of genetic influences on spirituality. In The God Gene: How Faith is Hardwired into our Genes, he proposed that a quantitative measure of self-transcendence is partially heritable and may be correlated to a specific gene, VMAT2, involved in monamine metabolism. Hamer's speculations on the possible role of genetics in religious experience were featured in a cover story in Time magazine.
==== Reserve ==== On 1 September 2014, 21 and 23 SAS were moved from UKSF. They were placed under command of 1st Intelligence, Surveillance and Reconnaissance Brigade. In 2019 they were moved back to UKSF.
Sources: en.wikipedia.org
==== MeSH E05.200.249 – culture techniques ==== MeSH E05.200.249.249 – cell culture techniques MeSH E05.200.249.374 – coculture techniques MeSH E05.200.249.437 – diffusion chambers, culture MeSH E05.200.249.468 – embryo culture techniques MeSH E05.200.249.484 – organ culture techniques MeSH E05.200.249.617 – tissue culture techniques MeSH E05.200.249.750 – tissue engineering
=== Post-translational modifications === ECD-MS fragments can retain posttranslational modifications such as carboxylation, phosphorylation and O-glycosylation. ECD has the potential to do the top-down characterization of the major types of posttranslational modifications in proteins. It successfully cleaved 87 of 208 backbone bonds and provided the first direct characterization of a phosphoprotein, bovine β casein, simultaneously restricting the location of five phosphorylation sites. It has advantages over CAD to measure the degree of phosphorylation with a minimum number of losses of phosphates and for phosphopeptide/phosphoprotein mapping, which makes ECD a superior technique.
=== Legal status === The FDA granted the application for pegcetacoplan orphan drug designation. In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aspaveli, intended for the treatment of adults with paroxysmal nocturnal hemoglobinuria. The applicant for this medicinal product is Swedish Orphan Biovitrum AB (publ). Pegcetacoplan was approved for the treatment of paroxysmal nocturnal hemoglobinuria in the European Union in December 2021. FDA approved Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration (ARMD) in February 2023. In June 2024, the CHMP recommended the refusal of a marketing authorization for Syfovre, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration. The manufacturer requested a re-examination in July 2024. In September 2024, the CHMP continued to refuse a marketing authorization after a re-examination.
Sources: en.wikipedia.org
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.
Reversed-phase high-performance liquid chromatography and mass spectrometry are common for the peptide portion. Copper content is usually determined by inductively coupled plasma techniques or by spectrophotometry. Ultraviolet-visible spectroscopy takes advantage of the visible absorption band of the copper complex.
Light, oxygen, and elevated temperature promote degradation of the peptide, and strongly acidic or alkaline conditions accelerate hydrolysis. The copper complex is generally more resistant to oxidation than the free peptide. Storage in a dry, dark, cold environment limits loss over time.
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.